{"id":55024,"date":"2023-03-21T13:03:02","date_gmt":"2023-03-21T12:03:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/"},"modified":"2023-03-21T13:03:02","modified_gmt":"2023-03-21T12:03:02","slug":"etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/","title":{"rendered":"Etiometry Announces CE Mark and Health Canada Authorization for Adult Use of AI-Based Algorithm that Detects Risk of Hypercapnia"},"content":{"rendered":"
\n

\nPreviously authorized for pediatric populations, critical care teams in Europe and Canada can now utilize Etiometry\u2019s IVCO2 Index\u2122 to determine the likelihood of inadequate carbon dioxide ventilation in adults\n<\/p>\n

BOSTON–(BUSINESS WIRE)–#CEmark<\/a>—Etiometry<\/a>, the leader in clinical decision-support software for critical care, today announced CE Mark and Health Canada authorization of its IVCO2 <\/sup>Index\u2122<\/a> for adult populations, which allows clinicians to visualize inadequate ventilation of carbon dioxide with other contextual data from the Etiometry Platform to help inform intervention decisions and get ahead of patient deterioration. The IVCO2 Index was first FDA-cleared for pediatric use in 2019 and now carries CE Mark and Health Canada licenses for both pediatric and adult use.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nOn the heels of January\u2019s FDA clearance of its IDO2 Index for adults \u2013 which was previously licensed for adult use by Health Canada and CE Marked in 2022 \u2013 Etiometry continues to seek authorizations for all of its risk algorithms to be used for both pediatrics and adults in the U.S., Canada and Europe.\n<\/p>\n

\n\u201cWe are serious in our pursuit to expand authorizations of all four of our current risk indices,\u201d said Shane Cooke, CEO of Etiometry. \u201cWhat drives us forward is knowing how our precision analytics bring situational awareness to strained care teams to help mitigate risk and enhance patient outcomes.\u201d\n<\/p>\n

\nUsing mathematical models of human physiology to determine the likelihood a patient is experiencing inadequate carbon dioxide (CO2) ventilation or hypercapnia, Etiometry\u2019s IVCO2 Index continuously tracks the probability that a patient\u2019s arterial blood gas sample has a partial pressure of CO2 (PaCO2) less than 50 mmHg – with the ability to select patient-specific thresholds at the bedside.\n<\/p>\n

\nThe IVCO2 Index provides care teams an additional safety net to detect deterioration in patients with conditions that require tight control of PaCO2 or when V\/Q mismatch can hamper the management of PaCO2.\n<\/p>\n

\nThe IVCO2 Index, along with Etiometry\u2019s other risk indices<\/a>, indicate the probability a patient will experience a harmful physiologic state and can also be embedded into the Etiometry Platform\u2019s growing list of automated clinical pathways to improve length of stay and decrease ventilation time.\n<\/p>\n

\nAbout Etiometry
\n
<\/b>Founded in 2010, Etiometry is the leader in clinical decision-support software designed to help clinicians in the intensive care setting make data-based decisions regarding their patients\u2019 care and treatment. The company\u2019s technologies provide valuable clinical insight and analysis to support early recognition of subtle changes in patients\u2019 conditions to avoid complications and speed recovery. Etiometry has eight FDA clearances and four Health Canada approvals and CE markings. With roots in pediatric ICUs, Etiometry\u2019s software is utilized by some of the world\u2019s top academic medical centers, 20 of the Best Children\u2019s Hospitals, ranked by U.S. News & World Report<\/i>, 4 out of 5 of the highest ranked children\u2019s hospitals in Newsweek\u2019s<\/i> Top Specialty Hospitals in the World and a growing number of top adult hospitals. Etiometry is committed to improving patient outcomes, increasing clinical efficiency, and lowering the cost of care through the more effective use of data.\n<\/p>\n

\nThe Etiometry Platform<\/b> is an end-to-end data management software solution for the collection, analysis, visualization, and archiving of ICU clinical data. It is designed to facilitate the use of all available data to support the anticipation and management of the dynamic condition of patients requiring intensive care. To learn more, visit www.etiometry.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia<\/b>
Andrew Young
\n
615-603-1574
\n
Andrew@hencove.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Previously authorized for pediatric populations, critical care teams in Europe and Canada can now utilize Etiometry\u2019s IVCO2 Index\u2122 to determine the likelihood of inadequate carbon dioxide ventilation in adults BOSTON–(BUSINESS WIRE)–#CEmark—Etiometry, the leader in clinical decision-support software for critical care, today announced CE Mark and Health Canada authorization of its IVCO2 Index\u2122 for adult populations, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55024","6":"format-standard","7":"category-industry"},"yoast_head":"\nEtiometry Announces CE Mark and Health Canada Authorization for Adult Use of AI-Based Algorithm that Detects Risk of Hypercapnia - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Etiometry Announces CE Mark and Health Canada Authorization for Adult Use of AI-Based Algorithm that Detects Risk of Hypercapnia - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Previously authorized for pediatric populations, critical care teams in Europe and Canada can now utilize Etiometry\u2019s IVCO2 Index\u2122 to determine the likelihood of inadequate carbon dioxide ventilation in adults BOSTON–(BUSINESS WIRE)–#CEmark—Etiometry, the leader in clinical decision-support software for critical care, today announced CE Mark and Health Canada authorization of its IVCO2 Index\u2122 for adult populations, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-21T12:03:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230321005034\/en\/1740737\/21\/IVC02.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Etiometry Announces CE Mark and Health Canada Authorization for Adult Use of AI-Based Algorithm that Detects Risk of Hypercapnia\",\"datePublished\":\"2023-03-21T12:03:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\\\/\"},\"wordCount\":587,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230321005034\\\/en\\\/1740737\\\/21\\\/IVC02.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\\\/\",\"name\":\"Etiometry Announces CE Mark and Health Canada Authorization for Adult Use of AI-Based Algorithm that Detects Risk of Hypercapnia - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230321005034\\\/en\\\/1740737\\\/21\\\/IVC02.jpg\",\"datePublished\":\"2023-03-21T12:03:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230321005034\\\/en\\\/1740737\\\/21\\\/IVC02.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230321005034\\\/en\\\/1740737\\\/21\\\/IVC02.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Etiometry Announces CE Mark and Health Canada Authorization for Adult Use of AI-Based Algorithm that Detects Risk of Hypercapnia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Etiometry Announces CE Mark and Health Canada Authorization for Adult Use of AI-Based Algorithm that Detects Risk of Hypercapnia - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/","og_locale":"en_US","og_type":"article","og_title":"Etiometry Announces CE Mark and Health Canada Authorization for Adult Use of AI-Based Algorithm that Detects Risk of Hypercapnia - Pharma Trend","og_description":"Previously authorized for pediatric populations, critical care teams in Europe and Canada can now utilize Etiometry\u2019s IVCO2 Index\u2122 to determine the likelihood of inadequate carbon dioxide ventilation in adults BOSTON–(BUSINESS WIRE)–#CEmark—Etiometry, the leader in clinical decision-support software for critical care, today announced CE Mark and Health Canada authorization of its IVCO2 Index\u2122 for adult populations, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-21T12:03:02+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230321005034\/en\/1740737\/21\/IVC02.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Etiometry Announces CE Mark and Health Canada Authorization for Adult Use of AI-Based Algorithm that Detects Risk of Hypercapnia","datePublished":"2023-03-21T12:03:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/"},"wordCount":587,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230321005034\/en\/1740737\/21\/IVC02.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/","url":"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/","name":"Etiometry Announces CE Mark and Health Canada Authorization for Adult Use of AI-Based Algorithm that Detects Risk of Hypercapnia - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230321005034\/en\/1740737\/21\/IVC02.jpg","datePublished":"2023-03-21T12:03:02+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230321005034\/en\/1740737\/21\/IVC02.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230321005034\/en\/1740737\/21\/IVC02.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/etiometry-announces-ce-mark-and-health-canada-authorization-for-adult-use-of-ai-based-algorithm-that-detects-risk-of-hypercapnia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Etiometry Announces CE Mark and Health Canada Authorization for Adult Use of AI-Based Algorithm that Detects Risk of Hypercapnia"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55024","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55024"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55024\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55024"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55024"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55024"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}